Welcome to our dedicated page for Teleflex SEC filings (Ticker: TFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teleflex Incorporated (NYSE: TFX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Teleflex’s financial performance, strategic transactions, leadership changes, and capital allocation decisions.
Teleflex uses Form 8-K to report material events such as quarterly and year-to-date financial results, including revenue by region and by global product category (vascular access, interventional, anesthesia, surgical, interventional urology, OEM, and other). The company’s 8-K filings also explain its use of non-GAAP measures like adjusted revenue, adjusted constant currency revenue growth, and adjusted diluted earnings per share, with descriptions of the adjustments for items such as restructuring, impairment, acquisition and divestiture-related costs, separation expenses, regulatory compliance costs, intangible amortization, ERP implementation costs, and tax adjustments.
Filings further document significant corporate actions. For example, Teleflex has filed 8-Ks describing Equity Purchase Agreements to sell its Original Equipment Manufacturing and Development Services business to an affiliate of Montagu and Kohlberg, and to sell its acute care and interventional urology segments to Intersurgical Limited and related entities. These documents outline purchase price terms, closing conditions, regulatory approval requirements, and intended uses of proceeds, including share repurchases and debt reduction.
Governance and leadership developments are also captured in SEC filings. A recent Form 8-K details the departure of the company’s President and Chief Executive Officer, the appointment of Stuart A. Randle as Interim President and Chief Executive Officer, and the designation of Dr. Stephen K. Klasko as Chair of the Board, along with related compensation and severance arrangements.
On Stock Titan, these Teleflex filings are updated as they are released on EDGAR. AI-powered tools can help summarize complex disclosures, highlight key terms in 10-K and 10-Q reports, and surface notable items in Forms 4 and proxy statements, giving investors a clearer view of Teleflex’s financial reporting, insider activity, and governance structure without reading every page manually.
Teleflex Inc. (TFX) reported that Interim President and CEO Stuart A. Randle received an equity award in the form of restricted stock units. On January 13, 2026, he was granted 12,325 shares of common stock at a price of $0 per share, increasing his directly held beneficial ownership to 19,872 shares. The award was granted under the Teleflex Incorporated 2023 Stock Incentive Plan in connection with his appointment as Interim President and CEO.
The restricted stock units vest on the earlier of the date a permanent Chief Executive Officer begins employment with Teleflex or January 13, 2027, provided Randle continues to serve the company through that vesting date. This filing reflects an equity-based compensation grant rather than an open-market purchase or sale.
Teleflex Incorporated disclosed a major leadership change and shared that it has issued estimated preliminary financial information for the full year ended December 31, 2025 via a separate press release. The filing reports that Liam J. Kelly has departed his roles as President and Chief Executive Officer, effective at the end of the day on January 7, 2026.
Effective January 8, 2026, long‑time director Stuart A. Randle has been appointed Interim President and Chief Executive Officer, while continuing to serve on the Board. The Board also named Stephen K. Klasko, M.D., as independent Chair and engaged search firm Spencer Stuart to help identify a permanent CEO.
Under a letter agreement, Mr. Randle will receive a stipend of $140,000 per month and a restricted stock grant with a grant date fair value of $1.5 million, vesting on the earlier of the permanent CEO’s start date or the first anniversary of grant, subject to continued service. Mr. Kelly’s severance and equity treatment will follow his existing 2017 severance agreement, contingent on his executing a release of claims.
Teleflex Incorporated announced two major divestitures and a large capital return plan. The company agreed to sell its Original Equipment Manufacturing and Development Services business to an affiliate of Montagu and Kohlberg for $1,500,000,000 in cash, subject to customary adjustments, with a potential $90,000,000 termination fee payable to Teleflex if the buyer fails to close under certain conditions. It also agreed to sell its acute care and interventional urology segments to Intersurgical Limited for $530,000,000 in cash, also subject to customary adjustments. Both transactions require regulatory approvals and are expected to close in the second half of 2026, with outside dates extending into 2027 for the second deal. Teleflex primarily intends to use net proceeds to return capital to shareholders and reduce debt, and its board authorized a share repurchase program of up to $1 billion, which will be mainly funded from these transactions.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G (Amendment No. 5) disclosing a passive stake in Teleflex Inc. (TFX). The firm reported beneficial ownership of 4,569,043 shares, representing 10.3% of the common stock, as of 09/30/2025.
T. Rowe Price reported sole voting power over 4,556,673 shares and sole dispositive power over 4,569,043 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The reporting person is classified as an investment adviser (IA).
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC filed a Schedule 13G disclosing beneficial ownership in Teleflex Inc. (TFX). They reported 2,366,131 shares of common stock, representing 5.35% of the class as of 09/30/2025.
The filing lists shared voting power over 2,366,131 shares and shared dispositive power over the same amount, with no sole voting or dispositive power. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Teleflex (TFX) reported a sharp swing to loss on non-cash charges. For the quarter ended September 28, 2025, net revenues were $913,021, up from $764,375 a year ago, reflecting contributions from the newly acquired Vascular Intervention business. However, the company posted a net loss of $(408,892), driven primarily by a $403,925 goodwill impairment in Interventional Urology and a $100,000 impairment tied to Titan SGS.
Operating trends were mixed: gross profit rose to $451,642, but higher SG&A and R&D, plus restructuring and separation costs, pressured results. Year‑to‑date, revenue reached $2,394,579 while net loss was $(191,310). Teleflex closed the BIOTRONIK Vascular Intervention acquisition for €704.3 million ($825.2 million) and financed it with a $700 million delayed draw term loan and additional revolver borrowings. Total borrowings increased to $2,681,250, and cash from operations was $188,971 year‑to‑date as investing cash outflows reflected the acquisition.
The company is advancing plans to separate NewCo, with $32,144 in year‑to‑date separation costs. Shares outstanding were 44,194,408 as of November 4, 2025.
Teleflex Incorporated (TFX) furnished an earnings press release and slide presentation announcing results for the quarter ended September 28, 2025. The materials were provided under Items 2.02 and 7.01.
The press release includes non-GAAP metrics: adjusted revenue growth, adjusted constant currency revenue growth, and adjusted diluted EPS. Adjusted revenue excludes an increase in reserves tied to Italy’s medical device “payback” measure following a recent court ruling. Adjusted diluted EPS excludes, as applicable, restructuring and rationalization, impairment, acquisition/integration/divestiture items, separation costs for the RemainCo/NewCo plan, pension termination charges, EU MDR registration costs, intangible amortization, ERP implementation and related IT transition costs, tax adjustments, and dilutive shares impact.
The information is furnished, not filed, and is not incorporated by reference unless expressly stated. Exhibits include the earnings release (99.1) and conference call slides (99.2).
Teleflex (TFX) received an amended Schedule 13G/A from BlackRock, Inc. reporting beneficial ownership of 5,158,480 shares of common stock, representing 11.7% of the class as of 09/30/2025. BlackRock reports sole voting power over 5,053,017 shares and sole dispositive power over 5,158,480 shares, with no shared voting or dispositive power.
BlackRock certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes that iShares Core S&P Small-Cap ETF holds an interest in Teleflex common stock that is more than five percent of outstanding shares.
Janus Henderson Group plc is disclosed as a beneficial owner of Teleflex Incorporated common stock, reporting an aggregate 4,149,271 shares representing 9.4% of the class. The filing indicates no sole voting or dispositive power and instead reports shared voting and dispositive power over the reported shares.
The Janus Henderson Enterprise Fund is shown holding 2,885,870 shares (6.5%) with shared voting and dispositive power. The filing includes a certification that the shares were acquired and are held in the ordinary course of business and not to influence control. The document is signed by Kristin Mariani and contains a power of attorney authorizing certain officers to execute ownership filings.
Teleflex Inc. (TFX) Form 4: Director Stuart A. Randle executed an open-market purchase of 1,000 common shares on 08/05/2025 at a weighted-average price of $115.86 (trade range $115.53–$116.06). The transaction is coded “P,” confirming it was a direct–purchase rather than an option exercise or gift. After the buy, Randle’s direct ownership rises to 7,547 shares, an increase of roughly 15% in his personal stake.
No derivative securities were involved and there were no dispositions. Insider buying—especially by an independent director—can serve as a modest positive signal of management confidence and alignment with shareholder interests, though the dollar value (~$116k) is not large relative to Teleflex’s market capitalization.